http://ww5.komen.org/News.aspxFor the latest information on breast cancer and the impact this life-threatening disease continues to have across the world, consider this your primary resource. Our spokespeople and grassroots networks of millions work tirelessly to make a difference while putting a face to every news story. As the leading news source for breast cancer developments, statistics, trends, commentary, photos and video, we continually update the news-related content in order to keep you informed.http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356563A false positive mammogram can cause long term psychosocial harm, according to the results of a study published in the Annals of Family Medicine—in fact, three years later, women still suffer the psychological after effects of the scare.   A ... 4/29/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356518Women ages 50 to 74 who undergo mammography screening every other year have a similar risk of advanced stage disease and a lower cumulative risk of false positive results than those who get mammograms every year, according to the results ... 4/18/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356482Following a heart healthy lifestyle to reduce the risk for heart disease can also help prevent cancer, according to the results of a study published in Circulation.  The American Heart Association designed their educational program My Life Check® in order ... 4/17/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356467Breast cancer prognosis may be worse among black women than among white women regardless of the subtype of breast cancer. These results were presented at the 2013 annual meeting of the American Association for Cancer Research (AACR).  It’s long been ... 4/11/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356465The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor ... 4/9/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356464The Oncotype DX® Recurrence Score® result is a robust predictor of loco regional recurrence in node positive, estrogen receptor (ER) positive patients treated with adjuvant hormonal therapy and chemotherapy, according to the results of a study presented at the 2013 ... 4/9/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356345The U.S. Food and Drug Administration (FDA) has approved Kadcyla™ (ado trastuzumab emtansine, formerly known as T DM1) for the treatment of HER2 positive, metastatic breast cancer that has been previously treated with Herceptin® (trastuzumab) and taxanes, a class of ... 3/20/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356344The prognosis of triple negative breast cancer (TNBC) tends to be better among older women than among younger women, even though older women are less likely to receive aggressive treatment. These results were published in Breast Cancer Research and Treatment.  ... 3/19/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356285In a combined analysis of previous studies, higher intake of vegetables was linked with a modestly reduced risk of estrogen receptor (ER) negative breast cancer.  Vegetables did not, however, affect risk of overall breast cancer or risk of ER positive ... 3/6/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327356181There has been a dramatic increase in the number of women undergoing immediate breast reconstruction after mastectomy—and this increase correlates with an increase in the use of implants, according to the results of a study published in Plastic and Reconstructive ... 1/22/2013http://ww5.komen.org/KomenNewsArticle.aspx?id=19327355962Brachytherapy is tied to more wound and skin complications than the standard radiation technique, according to the results of a study published in the Journal of Clinical Oncology.   For women with early stage breast cancer who are treated with ... 10/29/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327355859Blood levels of proneurotensin, a precursor of the satiation hormone neurotensin, are associated with the development of breast cancer, diabetes, and cardiovascular disease, according to the results of a study published in the Journal of the American Medical Association.   ... 10/15/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327355692One year of therapy with Herceptin® (trastuzumab) appears to be optimal in the adjuvant setting for women diagnosed with HER2 positive early breast cancer, according to the results of two studies presented at the ESMO 2012 Congress of the European ... 10/3/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327355690Radiation exposure from x rays, mammograms, and other diagnostic tests prior to age 30 may increase the risk of breast cancer in women who carry BRCA1 or BRCA2 mutations, according to the results of a large, retrospective cohort study published ... 10/2/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327355507Breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits (sometimes referred to as chemo brain) after treatment, according to the results of a study published early online in the Journal of Clinical Oncology.   A large ... 9/17/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354955Aspirin and cancer risk is in the news again—and the link is still unclear. Two studies published early online in the Journal of Clinical Oncology evaluated the relationship between aspirin and cancer risk—one indicated that aspirin does not appear to ... 9/14/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354940Among women with node positive, estrogen receptor positive breast cancer, the Oncotype DX test provides information about expected recurrence risk and survival after treatment with chemotherapy and hormone therapy. These results were presented at the 2012 Breast Cancer Symposium.  Among ... 9/14/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354795Women who are obese when diagnosed with breast cancer are more likely to experience disease recurrence and more likely to die from the disease, according to the results of a study published in Cancer. 1   Breast cancer is the ... 9/5/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354771Although high mammographic breast density is associated with an increased risk of developing cancer, it does not appear to increase the risk of death among breast cancer patients, according to the results of a study published in the Journal of ... 8/26/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354770A study conducted in Greece found elevated rates of BRCA1 gene mutations in women with triple negative breast cancer, particularly those who had been diagnosed with cancer at a young age. These results were published in Breast Cancer Research and ... 8/26/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354754Compared with white women, black women have higher rates of triple negative breast cancer at both younger and older ages. These results were published in the Journal of the National Cancer Institute.  It’s long been known that rates of breast ... 8/22/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353779 In addition to reducing the risk of breast cancer recurrence, post lumpectomy radiation therapy improves survival among women with early breast cancer. These results—from a combined analysis of 17 previous studies—were published in The Lancet.      Surgery for early stage breast ... 8/16/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354679The combination of anastrozole (Arimidex®) and fulvestrant (Faslodex®) prolonged overall survival and progression free survival in postmenopausal women with previously untreated hormone receptor positive metastatic breast cancer compared to Arimidex alone, according to the results of a study published in ... 8/6/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354678In order to speed the availability of promising drugs for high risk, early stage breast cancer, the US Food and Drug Administration (FDA) has drafted new guidelines for clinical trials. These guidelines focus specifically on triple negative breast cancer.  Given ... 8/6/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354652A subset of triple negative breast cancers contains a genetic change that contributes to cancer growth and may be possible to target with drugs. These results were published in Nature.  Each year, more than 220,000 women are diagnosed with breast ... 7/27/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354651The U.S. Food and Drug Administration (FDA) has approved Afinitor® (everolimus) for use in combination with Aromasin® (exemestane) to treat postmenopausal women with advanced hormone receptor positive, HER2 negative breast cancer. The combination is intended for use in women who ... 7/27/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354642Women who are obese continue to have higher levels of estrogen despite treatment with aromatase inhibitors such as Arimidex® (anastrozole) and Femara® (letrozole)—and these higher estrogen levels could affect their response to treatment, according to the results of a study ... 7/24/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354639Women under 40 who use estrogen to manage menopausal symptoms after having their ovaries removed do not have an increased risk of breast cancer, but their older counterparts might, according to the results of a study published in Obstetrics and ... 7/23/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354638  Women who take fertility drugs and do not get pregnant have a slightly reduced risk of developing breast cancer before age 50 however, those who do experience a pregnancy lasting 10 weeks or more have a slightly increased risk—one ... 7/23/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354606  Metformin, a widely prescribed insulin lowering drug for diabetes, may reduce the risk of invasive breast cancer in postmenopausal women with diabetes, according to the results of a study published early online in the Journal of Clinical Oncology.   ... 7/2/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354603  Women who exercise and maintain a healthy weight have a reduced risk of breast cancer even if their exercise is limited to mild recreational physical activity, according to the results of a study published early online in the journal ... 6/29/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354540The U.S. Food and Drug Administration (FDA) has approved Perjeta® (pertuzumab) for the treatment of HER2 positive, metastatic breast cancer. The drug is approved for use in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy in patients who have not received ... 6/18/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354529Radiation therapy to the chest for the treatment of childhood cancer increases a girl’s risk of developing breast cancer at a young age, even if fairly low doses of radiation are given. These results were presented at the 2012 Annual ... 6/14/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354524  Among women with advanced, previously treated, HER2 positive breast cancer, trastuzumab emtansine (T DM1) an investigational drug that combines Herceptin(r)  (trastuzumab) and a chemotherapy drug resulted in better progression free survival than standard treatment. The results of this Phase ... 6/11/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354485Physical activity is associated with reduced mortality in patients with breast and colon cancer, according to a study published in the Journal of the National Cancer Institute. 1 So far, there is insufficient evidence to draw the same conclusion with ... 5/24/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354447The U.S. Food and Drug Administration (FDA) has approved a silicone gel filled breast implant manufactured by Sientra Inc for breast augmentation in women at least 22 years old and breast reconstruction in women of any age. As a condition ... 5/14/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354419Women with dense breasts or a first degree relative with breast cancer are twice as likely as average risk women to develop breast cancer in their 40s 1 and these women would benefit from beginning mammography screening at age 40 ... 5/3/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354418Cancer related fatigue (CRF) is common after treatment for early stage breast cancer, but new results indicate that the phenomenon fades over time, according to a study published in the Journal of Clinical Oncology.  Breast cancer is the most commonly ... 5/3/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354350Women with false positive test results for breast cancer may want to remain vigilant with screening, as false positive results could be associated with underlying pathology that may result in breast cancer, according to the results of a study published ... 4/13/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354310A study of young women found that pregnancy after a diagnosis of estrogen receptor positive breast cancer does not appear to increase the risk of cancer recurrence. These results were presented at the eighth European Breast Cancer Conference.      Breast cancer ... 3/30/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354305Exercise and cognitive behavioral therapy may reduce menopausal symptoms among young women who have been treated for breast cancer. These results were presented at the eighth European Breast Cancer Conference (EBCC 8).     For women with breast cancer, treatments such as ... 3/29/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354255  Postmenopausal women who take hormone therapy consisting of estrogen alone may have a reduced risk of developing or dying from breast cancer. These findings—from longer term follow up of the Women’s Health Initiative trial of estrogen alone—were published in ... 3/12/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354254  Among women who have estrogen receptor positive ductal carcinoma in situ (DCIS) of the breast, adjuvant (post surgery) treatment with tamoxifen may reduce the risk of subsequent breast cancer. These results were published in the Journal of Clinical Oncology.  ... 3/12/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354214Women who received CMF chemotherapy for breast cancer between 1976 and 1995 scored slightly lower than women with no history of cancer on tests of word learning, memory, and information processing. These results were published in the Journal of Clinical ... 3/1/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354187A study of families with Lynch Syndrome has expanded the list of cancers related to the condition carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were ... 2/20/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354166Among postmenopausal women with hormone receptor positive breast cancer, the likelihood of dying from breast cancer increases with age. These results were published in the Journal of the American Medical Association.   Of the more than 200,000 cases of breast ... 2/10/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354159Among healthy postmenopausal women at increased risk of breast cancer, the aromatase inhibitor Aromasin® (exemestane) reduces the risk of breast cancer but also increases bone loss. These results were published in Lancet Oncology.    Drugs that block the effects of estrogen ... 2/8/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354152Among women who undergo breast conserving surgery for invasive breast cancer, the likelihood of having a second surgery varies by institution and by surgeon. These results were published in the Journal of the American Medical Association.    Breast conserving surgery (also ... 2/5/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354106Among women with HER2 negative breast cancer that has not spread to distant sites in the body, the addition of Avastin to neoadjuvant (before surgery) chemotherapy may increase the likelihood of a complete response to treatment (a disappearance of detectable ... 1/30/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354061Among young women undergoing chemotherapy for breast cancer, use of the drug triptorelin to suppress ovarian function during treatment does not appear to improve post treatment menstrual function. These results were published in the Journal of Clinical Oncology.    Fertility preservation ... 1/13/2012http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354023A DCIS Score generated by the Oncotype DX breast cancer test provides information about how likely it is that breast ductal carcinoma in situ (DCIS) will recur. This may help guide decisions about whether women with DCIS need radiation therapy ... 12/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354022Among women with early stage breast cancer, use of brachytherapy to administer radiation therapy may result in more post operative complications than conventional external beam radiation therapy, and may also increase the likelihood that a woman will later require a ... 12/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354018Among women with metastatic, HER2 positive breast cancer, treatment with a combination of HER2 targeted therapies may produce better outcomes than treatment with only a single HER2 targeted therapy. These results were published in the New England Journal of Medicine ... 12/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354017Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression to a greater extent than Aromasin alone. The results of this Phase III clinical trial ... 12/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327354016Longer term follow of of the ABCSG 12 study continues to suggest that the bisphosphonate drug Zometa® (zoledronic acid) may improve outcomes among women with early stage, hormone receptor positive breast cancer. These results were presented at the 2011 CTRC ... 12/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353997The results of a Phase III clinical trial suggest that starting Herceptin® (trastuzumab) during chemotherapy for early stage, HER2 positive breast cancer may be more effective than starting Herceptin after chemotherapy has been completed. These results were published in the ... 12/4/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353977The US Food and Drug Administration (FDA) is revoking the approval of Avastin® (bevacizumab) for the treatment of advanced breast cancer. This decision does not affect the use of Avastin for other approved purposes.  Avastin is a targeted therapy that ... 11/23/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353962Women who have as few as three to six alcoholic beverages per week have a slightly increased risk of breast cancer. Heavier drinker further increases risk. These results were published in the Journal of the American Medical Association.  Many previous ... 11/16/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353961Among postmenopausal women who complete five years of tamoxifen for the treatment of early stage breast cancer, an additional five years of treatment with the aromatase inhibitor Femara® (letrozole) may improve overall survival. These results were published in the Journal ... 11/16/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353819Among postmenopausal women with early stage, hormone receptor positive breast cancer, five years of hormonal therapy with Femara® (letrozole) results in a lower risk of cancer recurrence than five years of tamoxifen. These results were published in Lancet Oncology.  The ... 11/9/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353818For women who do not have a BRCA1 or BRCA2 gene mutation, having a close relative with one of these mutations does not increase breast cancer risk. These results were published in the Journal of Clinical Oncology.  Inherited mutations in ... 11/9/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353803For breast cancer patients with a sentinel lymph node that appears free of cancer based on standard testing (hematoxylin eosin staining), detection of very small areas of cancer in the lymph node through additional, more sensitive testing (immunohistochemistry) does not ... 11/3/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353778Among women who start annual screening mammography at the age of 40, more than half will have a false positive result (the need to return for additional imaging even though no cancer is present) during the first 10 years of ... 10/27/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353777Making informed decisions about cancer screening involves understanding the benefits and the limitations of the test being used. No test is perfect, but in the case of recommended screening tests such as mammography the benefits are believed to outweigh the ... 10/27/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353628Among women with metastatic, HER2 positive breast cancer, trastuzumab emtansine (T DM1)—an investigational drug that combines Herceptin® (trastuzumab) and a chemotherapy drug—resulted in better progression free survival than standard chemotherapy and Herceptin. The results of this Phase II clinical trial ... 10/5/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353616Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression to a greater extent than Aromasin alone. The results of this Phase III clinical trial ... 9/30/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353494  In a study that evaluated two generations of women with BRCA1 or BRCA2 mutations, breast and ovarian cancers tended to be diagnosed at a younger age in the later generation. These results were published in Cancer.     Inherited mutations in ... 9/15/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353470Giving chemotherapy before breast conserving surgery is as effective against breast cancer recurrence as giving chemotherapy after breast conserving surgery. These results were presented at the 2011 Breast Cancer Symposium.  Breast conserving surgery (also referred to as lumpectomy) involves removal ... 9/12/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353467Researchers have developed a tool that considers several patient and treatment characteristics in order to predict the risk of lymphedema after axillary lymph node dissection (removal of several under the arm lymph nodes) for breast cancer. These results will be ... 9/12/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353464  Two studies presented at the 2011 Breast Cancer Symposium provide evidence that breast conserving therapy (lumpectomy plus radiation therapy) is as effective as mastectomy for young women with early stage breast cancer.       Surgery for early stage breast ... 9/9/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353441  A study conducted in Denmark reports that women age 60 or older who have small, low grade, hormone receptor positive breast cancers may not need adjuvant (post surgery) treatment with hormone therapy or chemotherapy. These results were published in ... 9/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353438  Mutations in the CHEK2 gene increase the risk of breast cancer, particularly among women who also have a family history of the disease. These results were published in the Journal of Clinical Oncology.    Mutations in the BRCA1 and BRCA2 ... 9/6/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353236  According to a survey of more than 1,800 US physicians, decisions about who should be referred for BRCA1 2 testing are not always consistent with guidelines. These results were published in Cancer.  Inherited mutations in two genes—BRCA1 and BRCA2—have ... 8/2/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353214  Detection of very small areas of cancer (micrometastases) in the sentinel lymph node through use of highly sensitive testing is not associated with breast cancer outcomes. These results were published in the Journal of the American Medical Association.   For ... 8/1/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353199  In a Phase III clinical trial, the addition of the PARP inhibitor iniparib to chemotherapy did not improve outcomes among women with metastatic triple negative breast cancer. These results—which differ from those of a prior Phase II clinical trial—were ... 7/27/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353170  Among women with HER2 positive breast cancer that has spread to the brain, treatment with Herceptin® (trastuzumab) and or chemotherapy can prolong survival. These results were published in Clinical Cancer Research.    Although important advances have been made in breast ... 7/21/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353176  Older breast cancer patients who have additional medical conditions have worse survival than patients without other illnesses.  These findings were recently published in the Journal of the National Cancer Institute.  According to results from previous studies, illness in addition ... 7/21/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353167  For women with HER2 positive breast cancer that worsens in spite of treatment with Herceptin® (trastuzumab), treatment with a combination of Herceptin and Afinitor® (everolimus) may provide a benefit. These results were published in the Journal of Clinical Oncology.     ... 7/18/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353085  For women with early stage triple negative breast cancer, treatment with breast conserving surgery plus radiation therapy may result in fewer cancer recurrences in or near the breast than mastectomy without radiation therapy. These results were published in the ... 6/23/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353049Improved Breast Cancer Outcomes Among Women Using Beta BlockersWomen who take beta blockers for high blood pressure and are diagnosed with breast cancer may have better outcomes than women who do not take beta blockers, according to findings from two ... 6/15/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353042  For women with BRCA1 or BRCA2 gene mutations, use of hormone replacement therapy after preventive removal of the ovaries and fallopian tubes does not appear to increase the risk of breast cancer. These results were presented at the 2011 ... 6/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353033  Flaxseed does not reduce hot flashes among postmenopausal women. These results were presented at the 2011 annual meeting of the American Society of Clinical Oncology.      Menopause—when menstrual cycles end and ovarian hormone production drops dramatically—produces symptoms such as ... 6/8/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353031  More Extensive Radiation Therapy May Provide Benefit in Early Breast Cancer      The addition of regional lymph node irradiation (radiation therapy to lymph nodes around the breast) may improve outcomes for some women with early breast cancer. These results ... 6/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353028  The chemotherapy drug paclitaxel can cause nerve damage in some patients. According to a study that will be presented at the 2011 annual meeting of the American Society of Clinical Oncology, specific genetic markers may eventually allow doctors to ... 6/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353026  The aromatase inhibitor Aromasin® (exemestane) reduces the risk of breast cancer in postmenopausal women at increased risk of the disease. The results of this Phase III trial were presented at the 2011 annual meeting of the American Society of ... 6/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353025  Women who are at increased risk of breast cancer may further increase their risk if they smoke. Smoking was also linked with an increased risk of lung and colon cancers. These findings will be presented at the 2011 annual ... 6/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353024  Among breast cancer patients treated with an aromatase inhibitor (a type of hormonal therapy), those with high insurance co payments are more likely to quit aromatase inhibitor treatment or not to take it as directed. These results were published ... 6/6/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327353007  The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 ... 6/2/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=19327352985  Researchers have developed a tool that can help guide decisions about which drug—tamoxifen or raloxifene (Evista®)—is the best choice for breast cancer prevention in high risk postmenopausal women. These results were published in the Journal of Clinical Oncology.      ... 5/27/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=15032385613  Breast cancers detected in the interval between screening mammograms tend to have more aggressive characteristics than cancers detected during screening mammography. These results were published in the Journal of the National Cancer Institute.  Interval breast cancers refer to breast ... 5/13/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453163Postmenopausal women who take hormone therapy consisting of estrogen alone may have a somewhat reduced risk of breast cancer. These findings—from longer term follow up of the Women’s Health Initiative trial of estrogen alone—were published in the Journal of the ... 4/11/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453148Annual breast cancer screening that includes magnetic resonance imaging (MRI) reduces the frequency of advanced breast cancers among women with a BRCA1 or BRCA2 mutation. These results were published in the Journal of Clinical Oncology. Inherited mutations in two genes—BRCA1 ... 4/6/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453113Among women age 67 or older, a diagnosis of ductal carcinoma in situ (DCIS) or Stage I breast cancer doesn’t appear to worsen survival survival is similar to that of older women without breast cancer. Diagnosis of more advanced breast ... 3/28/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453083After a sharp decline in breast cancer rates between 2002 and 2003 among non Hispanic white women in the US, overall breast cancer rates did not change significantly between 2003 and 2007. These results were published in Cancer Epidemiology, Biomarkers, ... 3/17/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453071Among women with previously treated, locally recurrent or metastatic breast cancer, treatment with the chemotherapy drug Halaven™ (eribulin mesylate) improved overall survival by 2.5 months. The results of this Phase III clinical trial were published in The Lancet. Metastatic breast ... 3/15/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453068Among women with a personal history of breast cancer, mammography can detect second cancers at an early stage, but may be less accurate than among women who have never had breast cancer. These results were published in the Journal of ... 3/10/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453067Women who are obese and not physically active may be more likely than other women to develop triple negative breast cancer (breast cancer that is estrogen receptor negative, progesterone receptor negative, and HER2 negative). These results were published in Cancer ... 3/10/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453049A study conducted in Florida suggests that too many women are undergoing open, surgical breast biopsies instead of less invasive needle biopsies. These results were published in the American Journal of Surgery.       If a woman has a breast lump ... 3/2/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442453006A large study conducted in the UK has reported that early use of menopausal hormone therapy (use before or soon after menopause) may increase breast cancer risk to a greater extent than later use. These results were published in the ... 2/9/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452979Social well being during the first year after a breast cancer diagnosis may have a beneficial effect on cancer outcomes. These results were published in the Journal of Clinical Oncology.       A diagnosis of breast cancer often affects a woman’s1/26/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452969Among women with early breast cancer and a sentinel lymph node that appears to be cancer free on routine evaluation, more extensive lymph node evaluation identifies small areas of cancer in approximately 16% of women. These small, hidden areas of ... 1/25/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452953Choice of treatment, choice of surgeon, and surgical margin (a measure of whether the cancer was completely removed) all appear to affect the risk of disease recurrence among women with ductal carcinoma in situ (DCIS) of the breast.  These findings ... 1/14/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452952Compared with chemotherapy alone, treatment with a combination of chemotherapy and the investigational drug iniparib improved overall survival by more than four months among women with metastatic, triple negative breast cancer. The results of this Phase II clinical trial were ... 1/14/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452940It may be safe for breast cancer survivors to lift weights, including upper body exercises, without increasing risk for lymphedema. These results were reported in the Journal of the American Medical Association. Lymphedema refers to swelling of the arm due ... 1/8/2011http://ww5.komen.org/Content.aspx?id=6442452934Despite professional recommendations and public support in favor of regular mammography, only about half of US women get an annual mammogram, even if they have insurance to cover the test. These results were presented at the 2010 San Antonio Breast ... 1/7/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452923The addition of the targeted drug Avastin® (bevacizumab) to chemotherapy did not improve outcomes among women receiving preoperative chemotherapy for early stage breast cancer. The results of this Phase III clinical trial were presented at the 2010 San Antonio Breast ... 1/4/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452922Among women with early, HER2 positive breast cancer, treatment with a combination of HER2 targeted therapies may produce better outcomes than treatment with only a single HER2 targeted therapy. This was the conclusion of two studies presented at the 2010 ... 1/4/2011http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452921Aromatase inhibitors—hormonal therapy drugs commonly used in the treatment of postmenopausal breast cancer—may increase the risk of heart disease. These results were presented at the 2010 San Antonio Breast Cancer Symposium. Tamoxifen and aromatase inhibitors are hormonal therapy drugs that ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452920In women diagnosed with estrogen receptor (ER) positive HER2 negative breast cancer, obesity may contribute to poorer survival rates. These results were presented at the 2010 San Antonio Breast Cancer Symposium. Obesity is a significant public health concern that can ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452919It appears that women with early breast cancer who are prescribed treatment with aromatase inhibitors (AIs) are more likely to discontinue or not follow through with this therapy if insurance copayments are high. These results were presented at the 2010 ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452918In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452917The Oncotype DX® breast cancer test may change treatment decisions for more than a third of women with early, estrogen receptor positive breast cancer. These results were presented at the 2010 San Antonio Breast Cancer Symposium. The Oncotype DX breast ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452916Among women at low risk of breast cancer, postmenopausal hormone therapy with estrogen alone may reduce the risk of breast cancer. These results—which warrant additional research and should not be considered conclusive—came from further review of the Women’s Health Initiative ... 12/22/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452911Among women with early breast cancer, the presence of circulating tumor cells (cancer cells in the bloodstream) increased the risk of cancer recurrence and shortened survival. These preliminary results were presented at the 2010 San Antonio Breast Cancer Symposium. Among ... 12/19/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452877Women with a history of breast cancer appear to prefer the antidepressant Effexor® (venlafaxine) over the antiseizure drug Neurontin® (gabapentin) for treatment of hot flashes. These findings were recently released in the Journal of Clinical Oncology. Hot flashes can be ... 12/2/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452876Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood related) cancers. It is not approved for patients with ... 12/2/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452854Lasofoxifene, a selective estrogen receptor modulator (SERM), appears to reduce the risk of breast cancer among postmenopausal women with osteoporosis. These findings were recently reported in the Journal of the National Cancer Institute. As a SERM, the investigational drug lasofoxifene ... 11/16/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=12884901888A significant proportion of patients with advanced cancers continue to undergo cancer screening, even though screening is unlikely to benefit these patients. These findings were recently reported in the Journal of the American Medical Association. Cancer screening can detect disease ... 10/25/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452711Consistent with what has been reported in the United States, use of the Oncotype DX® breast cancer test influenced treatment decisions for early stage breast cancer patients in Spain. These results were presented at the 35th European Society for Medical ... 10/19/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452702According to the results of a study conducted at the M. D. Anderson Cancer Center, women who are diagnosed with breast cancer and treated with chemotherapy while pregnant have a better disease free survival (survival without a cancer recurrence or ... 10/14/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452701According to the results of a small study, approximately 20% of women with triple negative breast cancer are carriers of a BRCA1 or BRCA2 gene mutation. Triple negative breast cancer patients with these mutations appear to have better survival than ... 10/14/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452681About 70% of breast cancer survivors reported in a recent study that they had difficulty having sex, according to an article published in the Journal of Sexual Medicine. The many physical and emotional changes that follow a cancer diagnosis can ... 10/6/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452673Among postmenopausal women with advanced, estrogen receptor positive breast cancer that has progressed or recurred after prior hormonal therapy, a 500 mg dose of Faslodex® (fulvestrant) appears to be more effective than the originally approved 250 mg dose. These results ... 10/5/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452672According to the results of a study conducted in Canada, the sharp drop in use of combined (estrogen plus progestin) hormone therapy that occurred between 2002 and 2004 was accompanied by a decrease in breast cancer incidence. These results were ... 10/5/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452665Men whose partners were diagnosed with breast cancer were 39% more likely to be hospitalized due to an affective disorder (major depression, bipolar disease, and other serious mood altering conditions) compared with men whose partners were not diagnosed with breast ... 10/4/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452558A study conducted in Norway suggests that for women between the ages of 50 and 69, a mammography screening program reduced the risk of death from breast cancer by 10%, and accounted for roughly one third of the decline in ... 9/27/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452462Among women with a BRCA1 or BRCA2 gene mutation, prophylactic mastectomy (preventive removal of the breasts) reduces the risk of getting breast cancer. Prophylactic salpingo oophorectomy (preventive removal of the fallopian tubes and ovaries) reduces the risk both breast and9/17/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452439Although alcohol is a well established risk factor for breast cancer, it may be more strongly linked with lobular breast cancer than with ductal breast cancer. These results were published in the Journal of the National Cancer Institute.       Research ... 9/6/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=12884901886A recent study of menopausal hormone therapy and risk of breast cancer reported that risk may vary by body weight and the type of hormone therapy. These results were published in Cancer Epidemiology, Biomarkers, & Prevention. As women reach menopause ... 8/26/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452369Postmenopausal women who consume a traditional Mediterranean diet may have a lower risk for breast cancer, according to a study published in the American Journal of Clinical Nutrition. A traditional Mediterranean diet—one that is rich in fish, olive oil, vegetables, ... 8/18/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452368Early stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal. These ... 8/18/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452226Less than half of early stage breast cancer patients with hormone sensitive disease completed the full dose and schedule of their hormonal therapy treatment. These findings were recently published in the Journal of Clinical Oncology. 1 The majority of breast8/17/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452216Underinsured African Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute. i The disparity in breast cancer mortality between ... 8/6/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452344Postmenopausal women with high breast density are at an increased risk of developing breast cancer, according to the results of a study published in the Journal of Clinical Oncology. 1 This risk increases with the use of postmenopausal hormone therapy. ... 8/5/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452278Among postmenopausal women with hormone receptor positive breast cancer, use of an aromatase inhibitor at some point in the course of adjuvant (post surgery) treatment results in a lower risk of cancer recurrence than use of tamoxifen only. Based on ... 7/24/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452264 Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib. These findings were recently published in the journal The Lancet . [1] , [2] Although most ovarian cancer patients initiall ... 7/24/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452250Men who carry the BRCA2 genetic mutation have a 7.1% chance of developing breast cancer by age 70 and an 8.6% chance of developing the disease by age 80, according to the results of a study published early online in ... 7/15/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452236A recent study suggests that regular use of fish oil supplements may reduce the risk of breast cancer. These findings were published in the journal of Cancer Epidemiology, Biomarkers & Prevention. 1 Dietary supplements are a booming business—Americans are spending ... 7/9/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452198Women with operable node positive breast cancer experienced a survival benefit from sequential administration of doxorubicin, cyclophosphamide, and Taxotere® (docetaxel). These findings were recently published in The New England Journal of Medicine. 1 Effective treatment of node positive breast cancer ... 6/21/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452195Tykerb® (lapatinib) plus Taxol® (paclitaxel) appears to provide benefit in the initial treatment of inflammatory breast cancer, according to results published in the Journal of Clinical Oncology. Inflammatory breast cancer (IBC) is the most aggressive and lethal form of breast6/17/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452194Even with longer term follow up, heart problems are not common among breast cancer patients treated with Herceptin® (trastuzumab). These results were published in the Journal of Clinical Oncology. 1 Twenty to 25 percent of breast cancers overexpress (make too ... 6/17/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452181A single dose of radiotherapy delivered at the time of surgery may be an effective alternative to external beam radiation delivered over several weeks among selected patients with early breast cancer. Findings of this international Phase III trial were published ... 6/15/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452175Among women with early breast cancer and no evidence of cancer in the sentinel lymph nodes, sentinel lymph node biopsy alone is as effective as more extensive lymph node surgery. These results were presented at the 2010 annual meeting of ... 6/11/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452174It appears that in metastatic breast cancer, the biologic characteristics of liver metastases sometimes differ from those of the primary tumor. This finding may affect treatment choices for metastases. Results of this retrospective study were presented at the 2010 annual ... 6/11/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452173Aromatase inhibitor associated arthralgia (AIAA)  is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs. New research ... 6/11/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452172Among women with early stage breast cancer and small amounts of cancer (micrometastases) in the sentinel lymph node, removal of additional lymph nodes (completion axillary lymph node dissection) does not appear to improve overall survival. The results of this study ... 6/11/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452138Among women aged 70 or older with Stage I, estrogen receptor positive breast cancer, treatment with lumpectomy and tamoxifen resulted in a higher rate of cancer recurrence but similar overall survival as treatment with lumpectomy, tamoxifen, and radiation therapy. These ... 6/2/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452134An expert panel provided consensus recommendations for appropriate prevention, surveillance and treatment of hypertension (high blood pressure) in patients treated with vascular endothelial growth factor (VEGF) signaling pathway inhibitors. These recommendations were recently published in the Journal of the National ... 6/2/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452115Among women with early breast cancer, those with very small areas of cancer (micrometastases) in the axillary lymph nodes tend to have a higher risk of recurrence than those whose lymph nodes are completely free of cancer. These results were ... 5/20/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452114Screening mammography in women under age 40 results in high rates of callbacks, low rates of cancer detection, and high rates of false positive results, according to the results of a study published early online in the Journal of the ... 5/13/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452113Among women with breast ductal carcinoma in situ (DCIS), evaluation of three molecular markers in a sample of DCIS tissue may provide information about the subsequent risk of invasive breast cancer. These results were published in the Journal of the ... 5/10/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452112  Women who gain weight in midlife may have an increased risk of developing postmenopausal breast cancer, according to research findings presented at the 2010 Annual Meeting of the American Association for Cancer Research. Research into lifestyle factors that influence ... 5/5/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452111 Among postmenopausal women at increased risk of breast cancer, use of either tamoxifen (Nolvadex®) or raloxifene (Evista®) can substantially reduce the risk of breast cancer. The reduction in risk was somewhat greater with tamoxifen (50% versus 38% with raloxifene), but ... 5/3/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452110  Blood levels of epidermal growth factor receptor (EGFR) may be elevated in women up to 17 months prior to a diagnosis of breast cancer. These findings were recently presented at the American Association for Cancer Research 101st Annual Meeting. ... 4/30/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452016Adolescent girls who consume alcohol may have an increased risk of developing benign breast disease as young women, according to a study published in Pediatrics. Benign breast disease may increase risk for developing breast cancer. Previous studies have linked alcohol ... 4/20/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452017Young girls with a large body size may have a decreased risk of postmenopausal breast cancer compared with thinner girls, according to a study published in Breast Cancer Research. Body weight is a factor that appears to influence not only ... 4/20/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452015Among women with breast cancer, those with a BRCA1 or BRCA2 gene mutation are much more likely than other women to develop a second breast cancer in the opposite breast. These results were published in the Journal of Clinical Oncology. ... 4/12/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452013Women over age 80 tend to receive less aggressive treatment and experience higher mortality from early stage breast cancer than their younger counterparts, according to a study published in the Journal of Clinical Oncology.1 Women over the age of 80 ... 4/6/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452014For women with metastatic, HER2 positive breast cancer, the combination of Herceptin® (trastuzumab) with epirubicin and cyclophosphamide appears to offer a promising treatment option with a relatively low rate of heart complications. These results were published in the Journal of ... 4/6/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452012Among older women who undergo breast conserving surgery (lumpectomy) for early breast cancer, a longer interval between surgery and the start of radiation therapy increases the risk of local cancer recurrence. These results were published in the British Medical Journal. ... 4/1/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452011Among women with advanced HER2 positive breast cancer, the investigational drug neratinib produced promising response rates and progression free survival. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology. Twenty to 25 percent ... 3/16/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452010Oncotype DX® Predicts Recurrence Risk in Node negative and Node positive Breast Cancer Treated with Tamoxifen or ArimidexAmong postmenopausal women with early, hormone receptor positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts ... 3/9/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452009Among women with HER2 positive, metastatic breast cancer that has progressed during treatment with Herceptin® (trastuzumab), the combination of Tykerb® (lapatinib) and Herceptin appears to be more effective than Tykerb alone. These results were published in the Journal of Clinical ... 3/3/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452008Among women who are at least one year beyond a diagnosis of early stage breast cancer, regular aspirin use may reduce the risk of breast cancer recurrence and death. These results were published in the Journal of Clinical Oncology. Nonsteroidal ... 2/19/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452007The U.S. Food and Drug Administration (FDA) has expanded its approval of lapatinib (Tykerb®) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2 positive and hormone receptor positive. In this setting, lapatinib is approved for use ... 2/2/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452006According to a study conducted in China, breast cancer patients with the highest soy consumption had a lower risk of breast cancer recurrence and a lower risk of death than patients with the lowest soy consumption. An editorial that accompanied ... 1/29/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452005Exercising and drinking green tea may help prevent depression among breast cancer survivors, according to the results of a study published in the Journal of Clinical Oncology. 1 Depression is a major concern among breast cancer patients and survivors. Some ... 1/28/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452004Among women with early breast cancer, use of the Oncotype DX® test changed oncologist treatment recommendations in approximately 32% of cases. Use of the test also increased oncologist confidence in the treatment recommendation and decreased patient anxiety. These results were ... 1/12/2010http://ww5.komen.org/KomenNewsArticle.aspx?id=6442452003  Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology. The majority of breast cancers are ... 1/4/2010